Bostock will succeed J. William Futrell, M.D., the company’s Co-Founder and Chairman since 2011, who will continue as a Board Director.
In a press release, GID BIO CEO William W. Cimino said, "The addition of Roy Bostock to our team is another great milestone for us. He's one of the best in business with unparalleled credentials. He was Chairman and CEO of D'Arcy Masius Benton & Bowles, a global communications company serving clients such as Procter & Gamble, General Motors, Coca-Cola, Phillip Morris and Mars. His range of expertise will be instrumental as we look to the future to complete our pivotal Phase III studies and prepare to bring cellular therapy to market."
Incoming Board Chairman Roy Bostock added, "I'm thrilled to join this visionary biotech company that could have an enormous impact on medicine. The future is cellular therapy and the GID BIO team is on the cusp of a breakthrough in regenerative medicine to treat significant diseases where there is no current solution. Cellular therapy could transform millions of lives and also reduce the staggering costs accompanying traditional surgery."